New Study Confirms Safety and Efficacy of In Vivo CRISPR Therapy
Intellia Therapeutics announced positive Phase 3 results for its drug lonvoguran ziclumeran in treating hereditary angioedema. A single infusion reduced attack rates by 87% compared to placebo, bringing the first in vivo gene-editing therapy closer to approval.
87% and Silence: Why Intellia's Success Marks the End of the 'Lifetime Medication' Era
[The Core]: What's Really Happening
On April 27, 2026, Intellia Therapeutics released results analysts had awaited for four years. The Phase 3 HAELO trial for lonvoguran ziclumeran (formerly NTLA-2002) in hereditary angioedema (HAE) met its primary endpoint and all secondary endpoints. The media will report: '87% reduction in attacks,' '62% of patients attack-free.' But let me tell you what's really happening.
This is not just a successful trial. It is the first-ever Phase 3 for an in vivo gene-editing therapy. Intellia has outpaced the entire industry. While CRISPR Therapeutics and Vertex sell ex vivo therapies (cells edited outside the body), Intellia has proven that an LNP particle with CRISPR/Cas9 can be injected into a vein, find the liver, edit the gene, and permanently switch off the disease.
Insider insight: The real number here isn't 87%. It's 100% of patients in the treatment group remained off long-term prophylactic therapy at the data cutoff. That means even the 38% who had rare breakthrough attacks did not need daily pills or weekly injections. The drug doesn't just reduce frequency—it changes the treatment paradigm from 'control' to 'liberation.'
Timeline and Context
The race for the first approved in vivo CRISPR drug has been ongoing for years:
- 2021 — Intellia becomes the first to administer in vivo CRISPR therapy to a human (NTLA-2001 for transthyretin amyloidosis).
- 2023-2024 — Phase 2 of lonvo-z shows 95% reduction in attacks.
- April 27, 2026 — Positive Phase 3 HAELO data announced.
- Concurrently — Rolling BLA submission to the FDA begins.
- Expected 2027 — Commercial launch in the US.
Key point: The trial enrolled 80 patients with HAE type 1 and 2. Baseline mean attack rate was 3.5 per month. The treatment group received a single 50 mg infusion, the control group received placebo. The evaluation period was 6 months.
Crucial detail you might have missed: After week 28, patients in the control group could cross over to lonvo-z. Early crossover data shows that those who switched experienced attack rates dropping 'nearly to zero' by week 36. This means delayed treatment still works—a critical factor for payers assessing cost-effectiveness.
Winners and Losers
Winners:
- Intellia Therapeutics (NASDAQ: NTLA) — Shares rose 10.6% after the announcement. But the real potential isn't this spike. Analysts model revenue of $815 million by 2029, with optimists projecting up to $6 billion. Current market cap is around $1.5 billion. If lonvo-z is approved, the multiplier could be 5-10x.
- John Leonard, CEO — He has led the company since 2016 and is finally nearing commercialization. His stock options are now worth tens of millions of dollars. But more importantly, his legacy: his team brought CRISPR to registration.
- Patients with HAE — There are about 150,000 worldwide. Current therapies: C1 inhibitor injections 2-3 times per week ($500,000+ per year), or oral drugs (Berotralstat, $400,000+). Lonvo-z: one shot and freedom.
- Gene therapy innovators — Intellia's success validates the entire LNP delivery platform for CRISPR. This paves the way for dozens of other liver targets, from hemophilia B to hypercholesterolemia.
Losers:
- Takeda (Takzyro, lanadelumab) — Their drug brings in about $2 billion annually. It's a monoclonal antibody requiring injections every two weeks. Lonvo-z is a direct competitor. If 62% of patients on lonvo-z need no further therapy, demand for Takzyro will plummet.
- CSL Behring (Berinert, Haegarda) — C1 inhibitors represent another $1.5 billion market. Also under threat.
- BioCryst Pharmaceuticals (Orladeyo, berotralstat) — Their oral drug requires daily dosing. Patients hate lifelong daily pills. Lonvo-z spells the end for Orladeyo in first-line treatment.
- Insurance systems (short-term) — Long-term, they save money. But the upfront cost of one lonvo-z course is estimated at $1.5-2.5 million. This will create a cashflow shock for budgets in 2027-2028.
What the Media Isn't Telling You
First and foremost: The HAELO protocol excluded patients with a history of hepatitis B and C, alcoholic liver disease, cirrhosis, or unstable liver enzymes. This is standard. But it means we don't know how lonvo-z works in patients with compromised livers. And there are many such adults with HAE.
Second—a non-obvious insight: The 62% attack-free rate at 6 months is lower than the 73% seen in Phase 2 at 50 mg. What happened? Answer: Phase 2 had only 11 patients in the 50 mg group. The small sample size gave an inflated estimate. Phase 3 with 52 patients showed the real figure—62%. Still impressive, but important for realistic forecasting.
Third: In the treatment group, one patient had a Grade 2 ALT elevation at week 2 post-infusion. It resolved spontaneously within a week without treatment. But this is a reminder: CRISPR liver editing is not 100% safe. In the Nex-z trial for ATTR, a Grade 4 elevation led to an FDA clinical hold. Lonvo-z has been clean so far, but long-term follow-up continues.
Fourth—an insider-level insight: Marc Riedl, the lead investigator of HAELO, stated directly: 'At least half, and likely more than half, of my patients still discuss breakthrough attacks, symptoms, and treatment burden.' So despite existing multi-billion-dollar therapies, the unmet need is enormous. Lonvo-z fills this gap. But—and this is important—Riedl also noted that some patients are 'satisfied with current therapy' and are unwilling to risk gene editing due to fears about long-term safety. Patient education will be a key barrier to commercialization.
Fifth: The FDA granted lonvo-z RMAT (Regenerative Medicine Advanced Therapy) and Orphan Drug designations. This enabled rolling BLA and priority review. But final approval is not guaranteed. The EMA granted PRIME designation, but the European pathway will take another 12-18 months after the FDA.
Forecast: Next 30 Days and 90 Days
Next 30 days (through end of June 2026):
- Presentation of HAELO data at the EAACI (European Academy of Allergy and Clinical Immunology) congress in June 2026. Swimmer plots will show individual patient trajectories, revealing how long the effect lasts and whether late relapses occur.
- The FDA may officially confirm the completion date for the rolling BLA review. Intellia plans to finish submission in the second half of 2026, meaning a PDUFA date in the first half of 2027.
Next 90 days (through end of August 2026):
- Full publication in the New England Journal of Medicine or The Lancet. Data on all 80 patients, including the crossover group, will be released. Expect that by week 36, attack rates in crossover patients drop to 0.1-0.2 per month.
- Analysts will revise price targets for NTLA. Current consensus is $25-30. If safety data remain clean, targets could rise to $40-50.
- Intellia will begin negotiations with ICER (Institute for Clinical and Economic Review) on pricing. ICER typically recommends $1-1.5 million per QALY. But for ultra-rare diseases with $500,000+ annual treatment costs, the price could be $2-2.5 million.
Longer-term forecast (12-18 months):
- FDA approval of lonvo-z in the first half of 2027. This will be a historic moment—the first approved in vivo CRISPR therapy in the world.
- US launch in June-July 2027. First 12 months sales: $150-200 million. By 2029: $800 million to $1 billion.
- EMA approval will follow the FDA with a 6-9 month lag. European approval by end of 2027 or early 2028.
But there's a risk no one is talking about: The Nex-z program (ATTR) remains on clinical hold after a Grade 4 enzyme elevation. If the FDA requires Intellia to provide additional safety data for the entire LNP platform, it could affect lonvo-z. Unlikely, but possible.
Bottom line: Intellia has achieved the impossible. They turned CRISPR from a lab tool into a drug. Now the question is not about science, but about price, access, and trust. The next 12 months will show how ready the world is to pay for gene editing.
— Editorial Team
